EEF1A1: A Potential Drug Target and Biomarker (G1915)

Target Name: EEF1A1

NCBI ID: G1915

EEF1A1

EEF1A1: A Potential Drug Target and Biomarker

EEF1A1 is a protein that is expressed in various tissues throughout the body. Its function is not well understood, but it is known to be involved in several cellular processes. Recent studies have suggested that EEF1A1 may have potential as a drug target or biomarker. In this article, we will explore the potential of EEF1A1 as a drug target and biomarker, and discuss its potential clinical applications.

Drug Target Potential

One of the most promising aspects of EEF1A1 is its potential as a drug target. The protein is known to be involved in several cellular processes, including cell signaling, angiogenesis, and inflammation. Several studies have suggested that EEF1A1 may be a potential drug target due to its unique structure and its involvement in several signaling pathways.

For example, EEF1A1 has been shown to be involved in the TGF-β signaling pathway. This pathway is known to play a role in cell proliferation, differentiation, and angiogenesis. Additionally, EEF1A1 has been shown to be involved in the FGF signaling pathway, which is involved in cell signaling and proliferation.

EEF1A1 has also been shown to be involved in the Wnt signaling pathway. This pathway is involved in cell signaling and development, and is a potential target for anti-inflammatory drugs.

Biomarker Potential

In addition to its potential as a drug target, EEF1A1 has also been suggested as a potential biomarker for several diseases. The protein is known to be involved in several cellular processes, including cell signaling and angiogenesis. This suggests that it may be a useful biomarker for diseases associated with these processes, such as cancer, cardiovascular disease, and neurodegenerative diseases.

EEF1A1 has also been shown to be involved in the formation of blood vessels, which is a critical step in the development of many diseases. This suggests that it may be a useful biomarker for diseases associated with the formation of blood vessels, such as cardiovascular disease and hypertension.

Clinical Applications

The potential clinical applications of EEF1A1 are vast and varied. One of the most promising applications is its potential as a drug target for diseases associated with cellular processes that are not well understood, such as cancer and neurodegenerative diseases.

EEF1A1 may also be a useful biomarker for diseases associated with the formation of blood vessels, such as cardiovascular disease and hypertension. Additionally, the protein may be used as a target for drugs that target the TGF-β and FGF signaling pathways, which are involved in cell signaling and proliferation.

Conclusion

EEF1A1 is a protein that has been shown to be involved in several cellular processes throughout the body. Its function is not well understood, but it is known to be involved in several processes that are important for cellular growth and development. As a result, EEF1A1 has potential as a drug target or biomarker. Further research is needed to fully understand its function and its potential clinical applications.

Protein Name: Eukaryotic Translation Elongation Factor 1 Alpha 1

Functions: This protein promotes the GTP-dependent binding of aminoacyl-tRNA to the A-site of ribosomes during protein biosynthesis. Plays a role in the positive regulation of IFNG transcription in T-helper 1 cells as part of an IFNG promoter-binding complex with TXK and PARP1 (PubMed:17177976)

The "EEF1A1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EEF1A1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets